{
    "body": "Which medication should be administered when managing patients with suspected acute opioid overdose?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/9562190", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8907145", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11015242", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11130352", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1470965", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21044832", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17849242"
    ], 
    "ideal_answer": [
        "Naloxone is opioid anagonist that should be administered for all patients with suspected acute opioid overdose. Intravenous naltrexone hydrochloride is usually administered, however, other formulations, including enteral methylnaltrexone, nebulized naloxone and subcutaneous naloxone, are under investigation and can be used under certain circumstances."
    ], 
    "exact_answer": [
        "naloxone"
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D062787", 
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000701", 
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009292"
    ], 
    "type": "factoid", 
    "id": "5149f494d24251bc0500004c", 
    "snippets": [
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 145, 
            "text": "Opioid overdose has a high mortality, but is often reversible with appropriate overdose management and naloxone (opioid antagonist). ", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21044832", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1691, 
            "offsetInEndSection": 1782, 
            "text": "Training clinicians how to manage an opioid overdose and administer naloxone was effective.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21044832", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 2841, 
            "offsetInEndSection": 3085, 
            "text": "For patients who have ingested dextromethorphan and are sedated or comatose, naloxone, in the usual doses for treatment of opioid overdose, can be considered for prehospital administration, particularly if the patient has respiratory depression", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17849242", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 200, 
            "offsetInEndSection": 394, 
            "text": "Naloxone hydrochloride, an injectable opioid antagonist which reverses the respiratory depression, sedation and hypotension associated with opioids, has long been used to treat opioid overdose. ", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/11130352", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 394, 
            "offsetInEndSection": 567, 
            "text": "Experts have suggested that, as part of a comprehensive overdose prevention strategy, naloxone should be provided to heroin users for peer administration after an overdose. ", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/11130352", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 184, 
            "offsetInEndSection": 336, 
            "text": "Patients who received naloxone for known or presumed opioid overdose were formally evaluated one hour later for multiple potential predictor variables. ", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/11015242", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 741, 
            "offsetInEndSection": 843, 
            "text": "Patients with presumed opioid overdose can be safely discharged one hour after naloxone administration", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/11015242", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 202, 
            "text": "To determine whether naloxone administered i.v. to out-of-hospital patients with suspected opioid overdose would have a more rapid therapeutic onset than naloxone given subcutaneously (s.q.).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/9562190", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 540, 
            "offsetInEndSection": 677, 
            "text": "Subjects received either naloxone 0.4 mg i.v. (n = 74) or naloxone 0.8 mg s.q. (n = 122), for respiratory depression of <10 breaths/min. ", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/9562190", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1143, 
            "offsetInEndSection": 1371, 
            "text": "There was no clinical difference in the time interval to respiratory rate > or =10 breaths/min between naloxone 0.8 mg s.q. and naloxone 0.4 mg i.v. for the out-of-hospital management of patients with suspected opioid overdose. ", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/9562190", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 243, 
            "offsetInEndSection": 518, 
            "text": "To illustrate this problem, we report the case of a patient inappropriately treated with naloxone and the results of a retrospective review of the medical records of 15 consecutive patients with cancer treated with naloxone in the emergency department over a 5-month period. ", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/8907145", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1150, 
            "offsetInEndSection": 1360, 
            "text": "Management of opioid overdose, whether illicit or iatrogenic, requires the prompt and skillful use of opioid overdose, whether illicit or iatrogenic, requires the prompt and skillful use of opioid antagonists. ", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/1470965", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1431, 
            "offsetInEndSection": 1677, 
            "text": " The proportion of clinicians willing to use naloxone in an opioid overdose rose from 77% to 99% after training. Barriers to implementing training were clinician time and confidence, service resources, client willingness and naloxone formulation.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21044832", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 243, 
            "text": "Opioid overdose is rarely the primary cause of altered mental status in cancer patients receiving opioid therapy. The inappropriate administration of naloxone to reverse an abnormal mental status can cause severe withdrawal symptoms and pain. ", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/8907145", 
            "endSection": "sections.0"
        }
    ]
}